RECORDATI |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.8 EUR | 0.00% |
|
-1.89% | -0.06% |
| Apr. 24 | Global markets live: Heineken, AT&T Hasbro, Visa, Boeing... |  |
| Apr. 24 | CVC Said Mulling Options for Majority Stake in Recordati | MT |
| Sales 2024 * | 2.3B 2.47B | Sales 2025 * | 2.44B 2.61B | Capitalization | 10.04B 10.78B |
|---|---|---|---|---|---|
| Net income 2024 * | 477M 512M | Net income 2025 * | 523M 561M | EV / Sales 2024 * | 4.94 x |
| Net Debt 2024 * | 1.31B 1.4B | Net Debt 2025 * | 1.07B 1.15B | EV / Sales 2025 * | 4.56 x |
| P/E ratio 2024 * |
21.8
x | P/E ratio 2025 * |
19.6
x | Employees | 4,455 |
| Yield 2024 * |
2.88% | Yield 2025 * |
3.17% | Free-Float | 46.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on Recordati
More press releases
More news
| 1 day | -2.36% | ||
| 1 week | -0.29% | ||
| Current month | -4.76% | ||
| 1 month | -6.80% | ||
| 3 months | -2.28% | ||
| 6 months | +9.98% | ||
| Current year | -0.06% |
1 week
48.38
53.40
1 month
48.3853.40
Current year
47.2953.40
1 year
40.0053.40
3 years
34.5257.90
5 years
28.2657.90
10 years
11.1257.90
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Koremans
CEO | Chief Executive Officer | 61 | 21-11-30 |
Luigi la Corte
DFI | Director of Finance/CFO | 54 | 19-10-31 |
Andrea Recordati
CHM | Chairman | 52 | 98-04-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cathrin Petty
BRD | Director/Board Member | 50 | 18-06-11 |
Robert Koremans
CEO | Chief Executive Officer | 61 | 21-11-30 |
Andrea Recordati
CHM | Chairman | 52 | 98-04-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.52% | 5 M€ | +12.55% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 48.8 | -2.36% | 351,638 |
| 24-04-24 | 49.98 | -4.98% | 478,220 |
| 24-04-23 | 52.6 | +2.94% | 390,244 |
| 24-04-22 | 51.1 | +2.49% | 474,728 |
| 24-04-19 | 49.86 | +0.24% | 252,235 |
Real-time Borsa Italiana, April 25, 2024 at 11:44 am EDT
More quotes
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.;
- medicines for rare diseases (32.1%).
Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
48.8
EUR
Average target price
52.14
EUR
Spread / Average Target
+6.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.06% | 10.99B | |
| +24.17% | 562B | |
| -6.33% | 358B | |
| +19.90% | 322B | |
| +7.95% | 297B | |
| +13.45% | 219B | |
| +6.04% | 199B | |
| -10.51% | 196B | |
| -12.26% | 149B | |
| -6.47% | 146B |
- Stock Market
- Equities
- REC Stock
